SI-BONE IncSIBN
SIBN
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
21% more call options, than puts
Call options by funds: $4.29M | Put options by funds: $3.55M
13% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 45
8% more funds holding
Funds holding: 133 [Q3] → 143 (+10) [Q4]
2% less capital invested
Capital invested by funds: $572M [Q3] → $558M (-$13.4M) [Q4]
3.17% less ownership
Funds ownership: 98.08% [Q3] → 94.91% (-3.17%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
56%
upside
Avg. target
$26
82%
upside
High target
$32
127%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Citizens Capital Markets David Turkaly 31% 1-year accuracy 8 / 26 met price target | 127%upside $32 | Market Outperform Reiterated | 25 Feb 2025 |
Truist Securities Samuel Brodovsky 44% 1-year accuracy 4 / 9 met price target | 56%upside $22 | Buy Reiterated | 25 Feb 2025 |
Cantor Fitzgerald Ross Osborn 33% 1-year accuracy 15 / 46 met price target | 77%upside $25 | Overweight Reiterated | 25 Feb 2025 |
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target | 70%upside $24 | Buy Maintained | 25 Feb 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript

Negative
Zacks Investment Research
1 month ago
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.27 per share a year ago.

Neutral
GlobeNewsWire
1 month ago
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance
Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024

Neutral
Business Wire
1 month ago
Bruker Appoints Laura Francis to its Board of Directors
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a medical device company s.

Positive
Zacks Investment Research
1 month ago
Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy?
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neutral
GlobeNewsWire
1 month ago
SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025
SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Positive
Zacks Investment Research
3 months ago
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Positive
Zacks Investment Research
4 months ago
Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
The consensus price target hints at an 83.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Neutral
GlobeNewsWire
4 months ago
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.

Neutral
Seeking Alpha
4 months ago
SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript
SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - BofA Securities Young Li - Jefferies Drew Ranieri - Morgan Stanley Caitlin Cronin - Canaccord Richard Newitter - Truist Securities Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Charts implemented using Lightweight Charts™